Anticancer sustained-release gel injection containing neonatal blood vessel inhibitor

Abstract

A sustained-release gel injection comprises angiogenesis inhibitor, amphiphilic block copolymer, solvent and release regulator, wherein the mixture of amphiphilic block copolymer and solvent has temperature sensitive gelatinization characteristic, and can automatically become non-flowing degradable water insoluble gel, which can locally and slowly release drug at tumor foci for several weeks to several months, after injection into body. The preparation can be injected into or around tumor for treating solid tumors at different stages and metastatic tumors with remarkably reduced systemic toxicity of drug. The angiogenesis inhibitor is selected from alemtuzumab,ibritumomab, bevacizumab, rituximab, gemtuzumab ozogamicin, panitumumab, trastuzumab, celebrex, refecoxib, tositumomab, endostatain, engiostatin, toxitumomab, and cetuximab. The preparation has effects of controlling residual tumor cell relapse after operation and tumor can not be excised via operation, controlling complications at late stage of tumor, and enhancing treatment effect of chemotherapy and radiotherapy (particularly radioactive particles).

Description

A kind of anti-cancer slow-release gel injection containing neovascularization inhibitor (1) Technical field The invention relates to an anti-cancer slow-release gel injection containing angiogenesis inhibitor, which belongs to the technical field of medicines. Specifically, the invention relates to a slow-release gel preparation capable of stably releasing angiogenesis inhibitors and or slow-release microspheres in local solid tumors, mainly slow-release gel injections, and the slow-release gel preparation can be released at room temperature. The bottom is an aqueous solution, which can become a semi-solid or solid gel in the body of a warm-blooded animal, in which the angiogenesis inhibitor is partially or completely encapsulated in slow-release microspheres, and the angiogenesis inhibitor contained in the slow-release microspheres slowly spreads in the local tumor. The release time was further extended to several months. (2) Background technology Cancer has become the ...

AI Technical Summary

Problems solved by technology

Therefore, in most cases, the final sustained-release formulations are mostly solid shapes (eg, microspheres, tablets, or rods), which require a more complicated implantation process, and are prone to tissue trauma and even tumor cell seeding or dissemination

Solid implants cannot effectively cover the irregular tumor cavity after tumor resection, so the residual tumor cells cannot be effectively removed after surgery, and postoperative recurrence cannot be effectively controlled

In addition, organic solvents or high heat processes often lead to the degradation and denaturation of many anti-cancer active ingredients

In addition, the existing sustained-release preparations have obvious burst release, and the release cycle is short, which is not ideal for slow-growing tumors, especially cells in the G0 phase

Images